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Abstract
Valid estimation of a causal effect using instrumental variables requires that all of the
instruments are independent of the outcome conditional on the risk factor of interest and any
confounders. In Mendelian randomization studies with large numbers of genetic variants used
as instruments, it is unlikely that this condition will be met. Any given genetic variant could
be associated with a large number of traits, all of which represent potential pathways to the
outcome which bypass the risk factor of interest. Such pleiotropy can be accounted for using
standard multivariable Mendelian randomization with all possible pleiotropic traits included
as covariates. However, the estimator obtained in this way will be inefficient if some of the
covariates do not truly sit on pleiotropic pathways to the outcome. We present a method which
uses regularization to identify which out of a set of potential covariates need to be accounted for
in a Mendelian randomization analysis in order to produce an efficient and robust estimator of a
causal effect. The method can be used in the case where individual-level data are not available
and the analysis must rely on summary-level data only. It can also be used in the case where
there are more covariates under consideration than instruments, which is not possible using
standard multivariable Mendelian randomization. We show the results of simulation studies
which demonstrate the performance of the proposed regularization method in realistic settings.
We also illustrate the method in an applied example which looks at the causal effect of urate
plasma concentration on coronary heart disease.
1 Introduction
Instrumental variables can be used to estimate the causal effect of an exposure (also called a risk
factor) on an outcome from observational data. A variable is a valid instrument if it is: associated
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Figure 1: Directed acyclic graph showing the associations between the genetic variants (G1, . . . , Gp),
the risk factor (X), measured covariates which potentially give rise to pleiotropy (W1, . . . ,Wk),
potentially unknown and unmeasured confounders (U) and the outcome (Y ).
with the risk factor; independent of any confounders of the association between the risk factor and
the outcome; and independent of the outcome conditional on the risk factor and confounders. These
are the three instrumental variables assumptions (Greenland, 2000).
In Mendelian randomization studies, genetic variants are used as instrumental variables (Katan,
1986; Davey Smith and Ebrahim, 2003; Lawlor et al., 2008). Although genetic variants have many
properties which make them attractive candidates for instruments, one disadvantage is that a
single variant typically explains only a small amount of the variation in a risk factor. It is therefore
advantageous to combine information from a number of genetic variants. Given the proliferation
of genome-wide association studies (GWAS) in recent years, there is data available linking genetic
variants across the entire human genome to an enormous number of traits. Standard instrumental
variables and meta-analysis techniques allow us to combine the individual estimates given by each
of these genetic variants (Thompson and Sharp, 1999; Palmer et al., 2012). However, the more
genetic variants that are added to an analysis, the more likely that at least one of them will be
an invalid instrument. In particular, any given genetic variant could associate with a number of
traits other than the risk factor of interest. If any of these traits, which we refer to as covariates,
associate with the outcome via pathways which bypass the risk factor, then the third instrumental
variables assumption is violated and estimates of the causal effect will be biased. This is known as
pleiotropy. This scenario is illustrated via the directed acyclic graph in Figure 1.
There are many methods for estimating a causal effect in the presence of pleiotropy. However,
such methods typically require at least some of the genetic variants to be valid instruments. These
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include median-based estimators (Bowden et al., 2016), mode-based estimators (Hartwig et al.,
2017a; Guo et al., 2018) and the contamination mixture method (Burgess et al., 2019). The MR-
Egger method (Bowden et al., 2015) consistently estimates the causal effect without requiring the
assumption of no pleiotropy. However, the method relies on a different assumption that pleiotropic
effects are independent of the genetic variant-risk factor associations. This assumption is almost
as strong as the one it replaces and hypothesis testing based on the MR-Egger method often has
low power. Regularization methods proposed by Kang et al. (2016), Windmeijer et al. (2019) and
Rees et al. (2019) use ℓ1 penalization of the least squares equation to down-weight, and possibly
remove, invalid instruments. These methods implicitly assume that at least some of the instruments
are valid, and Kang et al. (2016) show that consistent estimation requires a majority of instruments
to be valid.
Jiang et al. (2019) proposed a constrained optimization approach to construct a weighting
scheme for the genetic variants that balances the pleiotropic effects. The weighting scheme can be
thought of as weights used to construct an allele score (Burgess and Thompson, 2013; Burgess et al.,
2016), which can then be used as an instrument in place of the genetic variants themselves. In Sec-
tion 3 we demonstrate that, in the case where the number of genetic variants is greater than the
number of covariates, the estimator obtained in this way is equivalent to that obtained using stan-
dard multivariable Mendelian randomization (Burgess and Thompson, 2015). The interpretation
of this is that we can account for covariates which give rise to pleiotropy by including them in a
multivariable Mendelian randomization model.
In practice, it will very often be the case that only a relatively small number of potential
covariates need to be included in a multivariable analysis in order to balance pleiotropy. That is,
only some of the traits will actually sit on pathways to the outcome which bypass the risk factor.
If this is the case, then the estimator of the causal effect obtained by a multivariable Mendelian
randomization analysis with all potential covariates included will be inefficient. Furthermore, if
there are more covariates than genetic variants, multivariable Mendelian randomization cannot
be performed, since this is akin to fitting a regression model with more predictor variables than
observations.
In this paper we propose a method for estimating a causal effect where any number of the
instruments are invalid due to measured pleiotropy. The method identifies the covariates, among a
set of potential covariates, which are on causal pathways from the genetic variants to the outcome,
and which therefore should be accounted for in a multivariable Mendelian randomization analysis.
Our approach is to fit a multivariable model which applies an ℓ1 penalty on the coefficients of
the genetic variant-covariate associations without applying penalization on the coefficient of the
genetic variant-risk factor association. The coefficients of the genetic variant associations with the
covariates which have little or no pleiotropic effects will be shrunk towards zero. We thus obtain a
more efficient estimator of the causal effect than we would by controlling for all covariates, and a less
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biased estimate than we would by ignoring the covariates. There are existing methods which apply
regularization to covariates (see, for example, Caner, 2009 and Fan and Liao, 2014). The method
of Lin et al. (2015) is in fact a two stage procedure which regularizes both the covariates and the
instruments. Our situation differs from these, however, in that we do not wish to apply penalization
to the coefficient of the risk factor, but only those of the covariates. That is, not all coefficients in
the model are penalized, which is a non-standard scenario. The approach is developed for use with
summarized data, that is, when the only data available are estimates of the genetic associations
with the risk factor, covariates and outcome, and their standard errors. This is typically the way
in which GWAS data are made available. It does not require any of the genetic variants to be free
of pleiotropy and, furthermore, since it is based on regularization, the method can be used in the
case where there are more covariates under consideration than instruments.
In Section 2 we formally define the model under consideration and demonstrate the inconsistency
of standard instrumental variables estimators if pleiotropy is ignored. In Section 3 we show how
to construct covariate balancing allele scores based on the constrained optimization approach using
summarized data, and demonstrate the equivalence of this approach to standard multivariable
Mendelian randomization. In Section 4 we describe our method for estimating the causal effect by
applying regularization to the coefficients of the genetic variant-covariate associations. In Section
5 we present the results of simulation studies which examine the performance of the method. In
Section 6 we demonstrate the approach with an applied example which looks at the effect of plasma
urate concentration on coronary heart disease.
2 The model
For individual i, let Yi be the outcome, Xi be the risk factor, Gi =
[
Gi1 · · · Gip
]
′
be genetic
variants and Wi =
[
Wi1 · · · Wik
]
′
be covariates potentially on the causal pathway between each
of the genetic variants and the outcome. The model we consider is given by
Xi = G
′
iβX + γXUi + εXi (1)
Wij = G
′
iβWj + γWjUi + εWij , j = 1, . . . , k (2)
Yi = θXi +W
′
i δ + γY Ui + εY i, (3)
where βX is a p × 1 vector of regression coefficients representing the associations between the p
genetic variants and the risk factor and βWj is a p× 1 matrix of regression coefficients representing
the associations between the p genetic variants and the jth covariate. The variable Ui represents
confounders of the associations between the risk factor, covariates and outcome. The parameters θ,
γX , γW1, . . . , γWk and γY are scalars and δ =
[
δ1 · · · δk
]
′
is a k×1 vector. It is assumed that the
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noise terms, εXi, εWi1, . . . , εWik, and εY i are independent of Ui and the genetic variants. It is also
assumed that the genetic variants are independent of each other (that is, no linkage disequilibrium)
and independent of Ui. By assuming that Ui is independent of the Gi, the second instrumental
variables assumption is satisfied and so the only violation of the assumptions is that of pleiotropy.
We let βˆXi, βˆWij and βˆY i be the estimates of the associations between the ith genetic variant
and the risk factor, the jth covariate and the outcome, respectively. We denote by βˆX and βˆY the
p × 1 vectors with ith elements βˆXi and βˆY i, respectively, and βˆW the p × k matrix with (i, j)th
element βˆWij . While instrumental variable analyses can be performed using individual-level data,
often in practice only summarized data in the form of these regression coefficients and their standard
errors are available to investigators. To aid applicability of the method, our method is formulated
using these summarized data only.
If the three instrumental variables assumptions are met, the causal effect parameter θ can be
consistently estimated using the two stage least squares method. In the first stage, the risk factor is
regressed on the genetic variants. In the second stage, the outcome is regressed on the fitted values
from the first stage. The regression estimate from the second stage is the estimate of the causal
effect. When only summarized data is available, the same estimator can be obtained by using the
inverse-variance weighted method (Burgess et al., 2013), which fits the regression model
βˆY j = θβˆXj + εj ,
where εj is assumed to be normally distributed with mean zero and variance equal to the variance
of βˆY j , denoted se
2
(
βˆY j
)
. That is, the inverse-variance weighted estimator is
θˆIV W =
βˆ′XSβˆY
βˆ′XSβˆX
,
where S is the p×p diagonal matrix with (j, j)th element se−2
(
βˆY j
)
. Under the model considered
here,
θˆIV W →p θ +
β′XΣGβW δ
β′XΣGβX
,
where →p denotes convergence in probability, βW =
[
βW1 · · · βWk
]
and ΣG is the p× p matrix
with (i, j)th element the covariance of the ith and jth genetic variant. Thus, θˆIVW is an inconsistent
estimator of the causal effect if βW δ 6= 0, that is, if pleiotropy is present.
3 Covariate balancing
Jiang et al. (2019) proposed weighting the genetic variants in such a way that the pleiotropic effects
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are balanced out. Such a weighting scheme, however, will tend to reduce the strength of the
association between the risk factor and the weighted genetic variants. A constrained optimization
approach was therefore proposed, which aims to maximise the covariance between the weighted
genetic variants and the risk factor under the constraint that the covariances between the weighted
genetic variants and each of the covariates are zero.
We can adapt the constrained optimization approach to the summarized data case as follows.
Letting α be a p × 1 vector of weights, cov (Gα,X) = α′ΣGβX and cov (Gα,W ) = α
′ΣGβW . We
thus wish to maximise with respect to α the objective function α′ΣGβˆX , subject to α
′ΣGβˆW = 0
and α′ΣGα = 1. The second constraint is a normalising condition so that a unique solution is
possible. When p > k, this can be solved in closed form by
α = α˜ =
ξ
ξ′ΣGξ
, (4)
where
ξ = βˆX − βˆW
(
βˆ′WΣGβˆW
)
−1 (
βˆ′WΣGβˆX
)
. (5)
The causal effect is then estimated by
α˜′ΣGβˆY
α˜′ΣGβˆX
. (6)
In practice, ΣG is unknown. However, since S is approximately proportional to ΣG, we can replace
ΣG by S in (4), (5) and (6). It is shown in the Appendix that this estimator is the same as that
obtained by fitting the weighted linear regression model
βˆY j = θβˆXj + δ1βˆWj1 + · · ·+ δ1βˆWjk + εj , (7)
where εj is normally distributed with mean zero and variance se
2
(
βˆY j
)
. This is the multivariable
inverse-variance weighted method (Burgess et al., 2015). Thus, we obtain an estimator of the
causal effect which controls for measured pleiotropy by using a standard multivariable Mendelian
randomization approach. However, as noted above, this estimator will be inefficient if any of the
covariates do not sit on pathways between the genetic variants and the outcome which bypass the
risk factor.
4 The regularization method
4.1 Estimating the causal effect
Suppose we believe that not all k covariates have pleiotropic effects. That is, that some of the δj ’s
are zero. We can induce sparsity in δ by including an ℓ1 penalty term in the least squares equation
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used for estimating the parameters in (7). That is, the parameter estimators are given by
argmin
θ,δ
1
2
(
βˆY − θβˆX − βˆW δ
)
′
S
(
βˆY − θβˆX − βˆW δ
)
+ λ
k∑
i=1
|δi| , (8)
where λ > 0 is a tuning parameter. This is not a standard Lasso problem, since we are not
penalizing all the parameters in the model. It is analogous to the some valid, some invalid IV
estimator (sisVIVE) of Kang et al. (2016), which also minimizes a sum of squares function with all
but one parameter subject to penalization. In the sisVIVE setup, invalid instruments are identified
by applying penalization on direct effects between the instruments and the outcome, but the causal
effect is not subject to penalization. Our case is different in that we do not seek to identify valid
instruments, but rather to identify pleiotropic covariates using summarized data.
Following a similar procedure to that of the proof of Theorem 3 in Kang et al. (2016), it is
shown in the Appendix that the estimator of θ obtained by (11), for a given value of λ, is equivalent
to that given by the following two step procedure.
1. Let
δˆλ = argmin
δ
(
βˆY − βˆW δ
)
′
S1/2Pb⊥S
1/2
(
βˆY − βˆW δ
)
+ λ
k∑
i=1
|δi| ,
where Pb⊥ = Ip − βˆX
(
βˆ′XSβˆX
)
−1
βˆ′X .
2. Let
θˆλ =
(
βˆY − βˆW δˆλ
)
′
SβˆX
βˆ′XSβˆX
.
The first step is now a standard Lasso problem. It induces shrinkage on the elements of δ, but
not on θ. Some of the elements of δ will be shrunk to zero, and the corresponding covariates are
effectively removed from the analysis. The second step can be interpreted as estimating θ by a
weighted regression of βˆY − βˆW δˆλ on βˆX .
An alternative estimator is obtained by dropping the covariates that are assigned a zero coeffi-
cient by the above procedure and then performing a standard multivariable analysis including the
remaining covariates. That is, the two step procedure is effectively used as a model selection tech-
nique. This is along the lines of, for example, the post-Lasso estimators of Belloni et al. (2012) and
Windmeijer et al. (2019), and the LARS-OLS hybrid estimator of Efron et al. (2004). The main
argument for using such post-regularization estimators is that they avoid potential bias that may
arise from the shrinkage of some of the regression coefficients. The cost is some loss in efficiency.
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4.2 The choice of tuning parameter
An important aspect of the method is the choice of tuning parameter, λ, which controls the level of
sparsity. A common approach to choosing λ is K-fold cross-validation. The set of genetic variants is
split into K folds, and the estimation procedure is performed, over a range of λ values, holding out
each fold in turn. The λ chosen is that which minimizes the mean, across each fold, of a particular
target function. A natural choice for the cross-validation target function is the mean squared error,
that is
1
p
(
βˆY − βˆW δˆλ − θˆλβˆX
)
′
S
(
βˆY − βˆW δˆλ − θˆλβˆX
)
. (9)
An alternative is to make the choice of λ in Step 1, independent of βˆX . That is, the cross-validation
target function is
1
p
(
βˆY − βˆW δ
)
′
S1/2Pb⊥S
1/2
(
βˆY − βˆW δ
)
. (10)
The use of (9) as target function will give the smallest test mean squared error and would be expected
to give the more precise estimation. The use of (10) will tend to select more covariates, since any
covariate-outcome effects which are mediated through the risk factor will not be discounted. It will
tend to therefore be more conservative in the sense that the standard deviation of the estimates
will be larger.
4.3 Two sample Mendelian randomization
An advantage of using summarized data is the possibility of using a two sample design for Mendelian
randomization. Under this design the genetic variant-risk factor associations and genetic-variant-
outcome associations are obtained from separate studies, assumed to be non-overlapping and with
similar underlying populations (Hartwig et al., 2017b). This allows for a large range combinations of
risk factors and outcomes to be considered, since we do not require each trait to have been included
in the same study. It also helps to mitigate against the so-called “winner’s curse” (Taylor et al.,
2014), which causes effect estimates to tend to be overestimated in single sample designs.
In the multivariable setting, a two sample approach may in fact involve many samples, with up
to one extra sample for each covariate. Again, this is a very flexible design in that it allows for any
trait that has been included in published GWAS data to be considered as a potential pleiotropic
covariate. It is a valid approach as long as each sample is non-overlapping with the genetic variant-
outcome sample and is drawn from a similar underlying population. In practice, these conditions
may be somewhat restrictive, particularly in a high-dimensional setting where there are many
covariates chosen from a number of GWAS datasets. Some studies are included in the datasets of
multiple GWAS consortia, and so there may be overlap with the genetic variant-outcome sample.
The extent to which any overlap exists should be checked to ensure it is not substantial. Note that
these issues are potential limitations of multivariable Mendelian randomization generally.
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4.4 Inference
Having estimated the causal effect, it is natural to wish to then perform inference, for example, via
producing confidence intervals. The post-regularization method will produce a standard error for
the causal effect, however the uncertainty is likely to be underestimated since it does not take in to
account the model selection event. The fundamental problem is that the same data is being used
to both select the covariates to be analysed and to do the analysis itself. A simple and pragmatic
approach to get around the problem is to use data splitting, which is a practice that goes (at least
as far) back as Cox (1975) (see also, for example, Fithian et al., 2014, for further discussion). The
idea is to randomly split a dataset into two. One set is used for model selection, the other for
inference. The obvious drawback is a loss of power, since the sample size is effectively halved. In
our setting, since we are using summarized data, data splitting is not an option. However, using
the same logic, we can propose a three sample study design. Here, an independent set of genetic
associations is used to perform the regularization method to identify the covariates that should
be accounted for. A standard two sample multivariable Mendelian randomization analysis is then
performed using separate datasets which contain genetic variant associations with the identified
covariates, risk factor and outcome. The independent dataset used for covariate selection should
be from a sample which is non-overlapping with those in the analysis datasets and from a similar
underlying population.
There is a growing literature on methods for performing inference post model selection without
requiring independent samples. Berk et al. (2013) (see also Bachoc et al., 2019) propose controlling
the family wise error rate across all possible models. In this way, correct coverage of confidence
intervals is guaranteed. The same data can be used for both model selection and inference, and
furthermore any selection technique can be used, even post-hoc, non-data driven ones. It is, however,
very conservative. Furthermore, it is computationally intensive to compute the critical values (the
authors note that it begins to be infeasible with m > 20).
Another strain of literature proposes the selective inference approach (Fithian et al., 2014;
Lee et al., 2016; Tibshirani et al., 2016; Taylor and Tibshirani, 2018), where inference is performed
conditional on a particular model being chosen. Lee et al. (2016) present a method for computing
confidence intervals specifically for the case where the model has been chosen using Lasso. They
show that the distribution of the parameter estimators conditional on the model selection event is a
truncated normal. The confidence intervals can be very wide when the parameter estimate is close
to the boundaries of the truncated normal, which will tend to occur when the signal is weak. It
could be expected that this may the case in our Mendelian randomization setting when instruments
are typically weak and the number of instruments is moderate. Furthermore, the method is derived
for fixed λ, and so is not valid if the tuning parameter is computed using the data under analysis,
for example using cross-validation.
Another approach is to use a double estimation procedure (Belloni et al., 2014). Under this
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approach, two model selections are performed using standard Lasso. The first selects covariates
in the model that regresses βˆX on βˆW . The second selects covariates in the model that regresses
βˆY on βˆW . The set of covariates used in the final model is the union of the two individual sets.
The procedure was developed for the scenario where the covariates are determinants of both the
risk factor and the outcome. Although this is not the case in the model described in Section 2,
in practice there may be associations between the covariates and the risk factor, in which case
this method would account for those. In any case, it should provide more conservative confidence
intervals than the two sample post-regularization approach.
5 Simulations
Data on 20,000 individuals were generated from the model given in (1), (2) and (3), with
Gij ∼ Binomial (2, π) ,
Ui, εXi, εWij , εY i ∼ N (0, 1) independently.
Four scenarios were considered, with different combinations of the number of genetic instruments
(p) and the number of covariates (k): p = 10, with k either 8 (scenario 1) or 12 (scenario 2); and
p = 80, with k either 70 (scenario 3) or 90 (scenario 4). We set π = 0.3, γX = γY = 1 and
γW1 = · · · = γWk = 1/k. The elements of βX were simulated uniformly on the interval (0.15, 0.3)
(scenarios 1 and 2) or (0.05, 0.12) (scenarios 3 and 4). The elements of the βWj ’s were simulated
uniformly on the interval (−0.2, 0.4) (scenarios 1 and 2) or (0.05, 0.12) (scenarios 3 and 4). These
values give average R2 statistics (that is, the proportion of the variance in the risk factor explained
by the genetic variants) of 10.0% (scenarios 1 and 2) and 11.7% (scenarios 3 and 4). The number
of covariates representing pleiotropic pathways (that is, the number of δj ’s not equal to zero) was
either 1, 2 or 4 in scenarios 1 and 2, and either 7, 21, or 35 in scenarios 3 and 4. The non-zero δj ’s
were simulated uniformly on the interval (−0.2, 0.3). Note that all instruments in this setting are
invalid and the pleiotropy is unbalanced. The causal effect was either θ = 0.2 or θ = 0.
For each scenario and combination of parameters, two independent datasets were generated. In
order to produce the summarized data, the genetic variant-risk factor / outcome associations were
estimated using simple linear regression on each genetic variant in turn using the first dataset. The
estimates of the genetic variant-outcome associations, and their standard errors, were produced in
the same way using the second dataset. For each of 1 000 replications the causal effect was estimated
using the following methods.
1. The inverse-variance weighted method (that is, ignoring all covariates) (IVW).
2. The two step regularization procedure (Reg).
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3. The multivariable inverse-variance weighted method including only the covariates given a
non-zero coefficient by the two step regularization procedure (Post-reg).
4. The multivariable inverse-variance weighted method with all covariates included (MV-All,
scenarios 1 and 3 only).
5. The multivariable inverse-variance weighted method with only truly pleiotropic covariates
included (Oracle).
When using the regularization procedure (that is, in methods b and c), the Lasso component of
Step 1 was performed using the glmnet package in R (Friedman et al., 2010). The set of λ values
used for cross-validation was the set generated by that package with the number of values set at
100. The target function for cross-validation was the mean squared error, given by (9), and number
of folds was K = 10. In scenarios 2 and 4, when more than p − 2 covariates were identified, the
tuning parameter was increased to the smallest value such that only p− 2 covariates were selected.
The inverse-variance weighted method, and the multivariable inverse-variance weighted methods
using the relevant set of covariates (that is, as used in methods c, d, and e), were performed using
the MendelianRandomization package in R (Yavorska and Burgess, 2017). The mean and standard
deviations of the estimates are shown in Table 1. Figure 2 (a)–(b) plots the mean squared error for
each scenario and method.
In each case, both the Reg and Post-reg estimators are less biased than IVW and have lower
standard deviations. The regularized estimators also have lower standard deviations than the full
multivariable estimator, and typically performed at least as well in terms of bias. The mean squared
error plots show that the regularized estimators, across all scenarios, sit below the IVW and full
multivariable estimators and above the oracle estimator.
The simulations described above represent scenarios where each of the genetic variants are
associated with each covariate, but where only some of the covariates have an association with the
outcome (that is, sparsity in the covariate effects on the outcome). In practice, it will often be
that all covariates under consideration are associated with the outcome, but only some of them
are associated with the genetic instruments (that is, sparsity in the genetic variant effects on the
covariates). In order to demonstrate that our method is an adequate proxy for this situation, the
simulations were repeated where all elements of δ were non-zero and covariates were removed in the
true model by setting columns of βW to zero. The mean and standard deviations of the estimates
from these simulations are shown in Table 2, and the mean squared error for each scenario and
method are shown in Figure 2 (c)–(d). The results are in line with the previous ones.
We next show the results of performing inference using methods discussed in Section 4.4. Using
the same set of simulations as above (where sparsity is in the covariate effects on the outcome), con-
fidence intervals were computed by performing the multivariable inverse-variance weighted method
using sets of covariates which were chosen as follows.
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1. All covariates ignored (IVW).
2. The two step regularization procedure using the mean squared error, given by (9), in cross-
validation (2 sample(a)).
3. The two step regularization procedure where cross-validation was performed independent of
the genetic variant-risk factor associations, that is, using (10) as target function (2 sample(b)).
4. The two step regularization procedure using an independent sample and the mean squared
error, given by (9), in cross-validation (3 sample(a)).
5. The two step regularization procedure using an independent sample and where cross-validation
was performed independent of the genetic variant-risk factor associations, that is, using (10)
as target function (3 sample(b)).
6. The double estimation procedure (Double est.).
7. Only truly pleiotropic covariates included (Oracle).
In each case, the model was fitted using the MendelianRandomization package in R with random
effects (that is, allowing over-dispersion, see Thompson and Sharp, 1999 and Burgess and Thompson,
2017) and 95% confidence intervals derived using the normal distribution. The means of the stan-
dard errors, coverage (that is, the proportion of confidence intervals containing the true causal
effect) and power (that is, the proportion of confidence intervals not containing zero) are shown in
Table 3 (for θ = 0.2) and Table 4 (for θ = 0). Note that in the θ = 0 case, power in fact refers to
the Type I error rate.
The results show that using the same data to do both covariate selection and inference results in
under-coverage, as expected. The three sample approach gives coverage close to the nominal level
of 0.95, particularly in scenarios 3 and 4 with larger numbers of instruments. The use of (10) in
cross-validation tends to give coverage closer to 0.95 than the use of (9), although not uniformly. It
also gives wider confidence intervals, suggesting that it is more conservative in covariate selection
(that is, tends to give lower levels of sparsity). The double estimation method, while producing
better coverage than the two sample approach, in most cases did not reach the 0.95 level. As
expected, the IVW method always had the lowest coverage and the full multivariable method (for
scenarios 1 and 3) always had the lowest power.
6 Investigating the causal effect of urate concentration on
coronary heart disease
We consider the study of White et al. (2016) looking at the effect of plasma urate concentration on
coronary heart disease. The study identified 31 genetic variants associated with urate concentration
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Table 1: Mean and standard deviation (SD) of estimates from the various methods when there is sparsity in the covariate effects
on the outcome. Scenarios 1 and 2 have either 1, 2 or 4 truly pleiotropic covariates and scenarios 3 and 4 have either 7, 21 or
35 truly pleiotropic covariates.
θ = 0.2 θ = 0
1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates 1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates
Method Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Scenario 1: p = 10, k = 8
IVW 0.219 0.077 0.240 0.103 0.289 0.146 0.024 0.075 0.040 0.105 0.086 0.142
Reg 0.204 0.060 0.203 0.066 0.217 0.090 0.005 0.053 0.007 0.063 0.012 0.088
Post-reg 0.201 0.066 0.198 0.073 0.210 0.096 0.004 0.059 0.003 0.070 0.006 0.099
MV-All 0.198 0.282 0.188 0.239 0.196 0.252 0.007 0.259 0.000 0.209 -0.015 0.314
Oracle 0.199 0.030 0.198 0.037 0.198 0.058 0.000 0.027 0.001 0.033 0.000 0.048
Scenario 2: p = 10, k = 12
IVW 0.222 0.075 0.251 0.107 0.279 0.146 0.022 0.073 0.045 0.105 0.092 0.146
Reg 0.205 0.050 0.212 0.065 0.219 0.095 0.003 0.044 0.008 0.060 0.028 0.089
Post-reg 0.203 0.056 0.208 0.072 0.213 0.104 0.000 0.049 0.005 0.066 0.021 0.093
Oracle 0.198 0.030 0.201 0.038 0.202 0.057 0.000 0.027 0.000 0.032 0.002 0.051
Scenario 3: p = 80, k = 70
IVW 0.290 0.110 0.478 0.194 0.678 0.243 0.095 0.110 0.279 0.199 0.480 0.238
Reg 0.200 0.050 0.214 0.080 0.231 0.113 0.014 0.045 0.035 0.079 0.053 0.106
Post-reg 0.181 0.060 0.184 0.088 0.185 0.121 0.003 0.055 0.013 0.084 0.018 0.117
MV-All 0.167 0.178 0.169 0.194 0.160 0.223 -0.005 0.157 0.003 0.192 0.001 0.211
Oracle 0.192 0.032 0.189 0.054 0.180 0.083 0.002 0.029 0.004 0.050 0.006 0.078
Scenario 4: p = 80, k = 90
IVW 0.294 0.112 0.485 0.185 0.666 0.249 0.097 0.109 0.291 0.196 0.466 0.245
Reg 0.201 0.053 0.221 0.087 0.255 0.125 0.016 0.045 0.039 0.082 0.072 0.113
Post-reg 0.180 0.066 0.188 0.097 0.211 0.134 0.004 0.055 0.013 0.093 0.035 0.124
Oracle 0.191 0.033 0.187 0.053 0.188 0.080 0.002 0.029 0.003 0.051 0.005 0.073
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Table 2: Mean and standard deviation (SD) of estimates from the various methods when there is sparsity in the genetic variant
effects on the covariates. Scenarios 1 and 2 have either 1, 2 or 4 truly pleiotropic covariates and scenarios 3 and 4 have either 7,
21 or 35 truly pleiotropic covariates.
θ = 0.2 θ = 0
1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates 1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates
Method Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Scenario 1: p = 10, k = 8
IVW 0.219 0.077 0.240 0.104 0.288 0.146 0.020 0.076 0.040 0.103 0.089 0.146
Reg 0.203 0.046 0.204 0.057 0.215 0.089 0.003 0.044 0.005 0.055 0.013 0.086
Post-reg 0.201 0.047 0.200 0.061 0.207 0.094 0.001 0.044 0.002 0.057 0.005 0.092
MV-All 0.197 0.176 0.199 0.172 0.204 0.199 0.000 0.164 0.000 0.146 0.002 0.171
Oracle 0.199 0.032 0.198 0.039 0.198 0.060 0.000 0.028 -0.001 0.035 -0.001 0.053
Scenario 2: p = 10, k = 12
IVW 0.222 0.076 0.251 0.107 0.280 0.147 0.023 0.075 0.051 0.107 0.080 0.146
Reg 0.205 0.044 0.212 0.061 0.223 0.094 0.005 0.040 0.013 0.057 0.023 0.088
Post-reg 0.201 0.045 0.206 0.062 0.217 0.094 0.002 0.040 0.008 0.059 0.018 0.088
Oracle 0.198 0.032 0.200 0.041 0.201 0.060 0.000 0.029 0.002 0.037 0.002 0.054
Scenario 3: p = 80, k = 70
IVW 0.290 0.112 0.478 0.194 0.678 0.243 0.096 0.112 0.284 0.193 0.484 0.243
Reg 0.212 0.056 0.237 0.087 0.253 0.118 0.020 0.052 0.047 0.082 0.068 0.112
Post-reg 0.197 0.053 0.208 0.083 0.207 0.116 0.007 0.049 0.022 0.079 0.027 0.112
MV-All 0.188 0.124 0.194 0.168 0.175 0.202 -0.001 0.116 0.011 0.158 -0.002 0.187
Oracle 0.191 0.040 0.189 0.063 0.180 0.092 0.001 0.037 0.006 0.059 0.003 0.086
Scenario 4: p = 80, k = 90
IVW 0.294 0.115 0.485 0.186 0.666 0.250 0.100 0.115 0.292 0.186 0.472 0.249
Reg 0.217 0.062 0.253 0.092 0.288 0.131 0.026 0.059 0.063 0.087 0.100 0.126
Post-reg 0.201 0.058 0.219 0.090 0.238 0.127 0.011 0.054 0.033 0.085 0.054 0.121
Oracle 0.191 0.044 0.188 0.063 0.186 0.089 0.002 0.041 0.005 0.059 0.008 0.084
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Figure 2: Logarithm of the mean squared errors for each scenario (S1–S4) and number of truly
pleiotropic covariates (01–35). Plots (a) and (b), where θ = 0.2 and θ = 0, respectively, show the
results from simulations where there is sparsity in the covariate effects on the outcome. Plots (c)
and (d), where θ = 0.2 and θ = 0, respectively, show the results from simulations where there is
sparsity in the genetic variant effects on the covariates.
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Table 3: Mean, standard deviation (SD), mean standard errors (SE), coverage (Cov) and power (Pow) of estimates from the
various methods (when there is sparsity in the covariate effects on the outcome) with θ = 0.2.
1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates
Method Mean SD SE Cov Pow Mean SD SE Cov Pow Mean SD SE Cov Pow
Scenario 1: p = 10, k = 8
IVW 0.219 0.077 0.040 0.729 0.958 0.240 0.103 0.054 0.667 0.920 0.289 0.146 0.074 0.595 0.852
2 sample (a) 0.201 0.066 0.050 0.894 0.922 0.198 0.073 0.056 0.888 0.865 0.210 0.096 0.073 0.859 0.788
2 sample (b) 0.201 0.146 0.081 0.900 0.794 0.192 0.143 0.082 0.900 0.757 0.209 0.132 0.090 0.883 0.714
3 sample (a) 0.197 0.074 0.059 0.937 0.891 0.200 0.080 0.065 0.922 0.839 0.208 0.118 0.086 0.914 0.745
3 sample (b) 0.196 0.213 0.097 0.951 0.763 0.194 0.114 0.094 0.939 0.708 0.205 0.135 0.102 0.928 0.666
Double est. 0.202 0.100 0.072 0.926 0.804 0.199 0.132 0.094 0.909 0.736 0.203 0.136 0.104 0.892 0.684
MV-All 0.198 0.282 0.190 0.961 0.425 0.188 0.239 0.196 0.963 0.386 0.196 0.252 0.190 0.957 0.418
Oracle 0.199 0.030 0.032 0.947 0.999 0.198 0.037 0.039 0.956 0.982 0.198 0.058 0.056 0.953 0.903
Scenario 2: p = 10, k = 12
IVW 0.222 0.075 0.041 0.726 0.967 0.251 0.107 0.055 0.658 0.928 0.279 0.146 0.074 0.607 0.826
2 sample (a) 0.203 0.056 0.049 0.910 0.911 0.208 0.072 0.060 0.878 0.855 0.213 0.104 0.072 0.810 0.789
2 sample (b) 0.201 0.087 0.082 0.948 0.706 0.204 0.089 0.085 0.923 0.703 0.213 0.114 0.090 0.868 0.695
3 sample (a) 0.201 0.057 0.053 0.940 0.908 0.205 0.086 0.071 0.930 0.811 0.207 0.118 0.090 0.882 0.702
3 sample (b) 0.200 0.098 0.096 0.962 0.673 0.203 0.111 0.100 0.948 0.633 0.200 0.131 0.113 0.928 0.581
Double est. 0.201 0.072 0.062 0.935 0.850 0.199 0.079 0.075 0.906 0.779 0.209 0.111 0.084 0.826 0.723
Oracle 0.198 0.030 0.032 0.955 0.997 0.201 0.038 0.040 0.956 0.986 0.202 0.057 0.057 0.957 0.909
Scenario 3: p = 80, k = 70
IVW 0.290 0.110 0.043 0.392 0.970 0.478 0.194 0.069 0.216 0.975 0.678 0.243 0.089 0.081 0.988
2 sample (a) 0.181 0.060 0.044 0.846 0.923 0.184 0.088 0.069 0.879 0.719 0.185 0.121 0.091 0.848 0.539
2 sample (b) 0.180 0.062 0.045 0.836 0.908 0.185 0.091 0.070 0.867 0.717 0.185 0.122 0.093 0.853 0.529
3 sample (a) 0.186 0.051 0.049 0.947 0.936 0.186 0.083 0.084 0.951 0.618 0.186 0.120 0.120 0.941 0.370
3 sample (b) 0.187 0.051 0.050 0.943 0.938 0.187 0.084 0.084 0.960 0.623 0.186 0.122 0.122 0.931 0.357
Double est. 0.185 0.058 0.048 0.871 0.918 0.185 0.084 0.073 0.911 0.720 0.191 0.114 0.096 0.895 0.522
MV-All 0.167 0.178 0.181 0.947 0.153 0.169 0.194 0.200 0.952 0.145 0.160 0.223 0.223 0.943 0.131
Oracle 0.192 0.032 0.033 0.950 1.000 0.189 0.054 0.054 0.942 0.941 0.180 0.083 0.080 0.939 0.615
Scenario 4: p = 80, k = 90
IVW 0.294 0.112 0.043 0.393 0.977 0.485 0.185 0.070 0.198 0.981 0.666 0.249 0.088 0.099 0.982
2 sample (a) 0.180 0.066 0.046 0.802 0.895 0.188 0.097 0.074 0.859 0.686 0.211 0.134 0.099 0.837 0.574
2 sample (b) 0.179 0.066 0.047 0.803 0.897 0.190 0.099 0.076 0.856 0.669 0.210 0.136 0.103 0.845 0.544
3 sample (a) 0.187 0.055 0.052 0.930 0.908 0.192 0.097 0.093 0.936 0.576 0.202 0.153 0.142 0.940 0.368
3 sample (b) 0.185 0.056 0.054 0.936 0.883 0.189 0.101 0.096 0.938 0.564 0.201 0.152 0.143 0.946 0.375
Double est. 0.185 0.063 0.050 0.874 0.884 0.188 0.093 0.080 0.912 0.648 0.206 0.134 0.113 0.888 0.521
Oracle 0.191 0.033 0.033 0.938 1.000 0.187 0.053 0.054 0.955 0.935 0.188 0.080 0.079 0.950 0.660
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Table 4: Mean, standard deviation (SD), mean standard errors (SE), coverage (Cov) and power (Pow) of estimates from the
various methods (when there is sparsity in the covariate effects on the outcome) with θ = 0.
1 / 7 Covariates 2 / 21 Covariates 4 / 35 Covariates
Method Mean SD SE Cov Pow Mean SD SE Cov Pow Mean SD SE Cov Pow
Scenario 1: p = 10, k = 8
IVW 0.024 0.075 0.040 0.707 0.293 0.040 0.105 0.053 0.647 0.353 0.086 0.142 0.073 0.587 0.413
2 sample (a) 0.004 0.059 0.044 0.905 0.095 0.003 0.070 0.053 0.901 0.099 0.006 0.099 0.067 0.863 0.137
2 sample (b) 0.000 0.171 0.072 0.924 0.076 0.000 0.125 0.075 0.906 0.094 0.001 0.138 0.081 0.874 0.126
3 sample (a) -0.003 0.100 0.051 0.936 0.064 0.002 0.065 0.060 0.934 0.066 0.000 0.089 0.074 0.904 0.096
3 sample (b) -0.002 0.148 0.086 0.950 0.050 0.007 0.105 0.079 0.942 0.058 0.001 0.110 0.091 0.934 0.066
Double est. 0.003 0.126 0.072 0.935 0.065 0.003 0.109 0.081 0.929 0.071 -0.007 0.277 0.104 0.916 0.084
MV-All 0.007 0.259 0.173 0.964 0.036 0.000 0.209 0.163 0.956 0.044 -0.015 0.314 0.170 0.955 0.045
Oracle 0.000 0.027 0.028 0.964 0.036 0.001 0.033 0.035 0.954 0.046 0.000 0.048 0.050 0.965 0.035
Scenario 2: p = 10, k = 12
IVW 0.022 0.073 0.039 0.746 0.254 0.045 0.105 0.054 0.653 0.347 0.092 0.146 0.074 0.556 0.444
2 sample (a) 0.000 0.049 0.045 0.916 0.084 0.005 0.066 0.053 0.886 0.114 0.021 0.093 0.065 0.815 0.185
2 sample (b) -0.001 0.071 0.072 0.941 0.059 0.005 0.081 0.074 0.928 0.072 0.016 0.093 0.078 0.881 0.119
3 sample (a) -0.001 0.053 0.050 0.944 0.056 0.005 0.073 0.060 0.907 0.093 0.017 0.103 0.078 0.860 0.140
3 sample (b) -0.005 0.086 0.089 0.960 0.040 -0.002 0.099 0.085 0.945 0.055 0.008 0.121 0.101 0.919 0.081
Double est. -0.002 0.059 0.057 0.933 0.067 0.003 0.073 0.066 0.922 0.078 0.025 0.108 0.080 0.838 0.162
Oracle 0.000 0.027 0.029 0.967 0.033 0.000 0.032 0.035 0.969 0.031 0.002 0.051 0.051 0.968 0.032
Scenario 3: p = 80, k = 70
IVW 0.095 0.110 0.042 0.376 0.624 0.279 0.199 0.067 0.209 0.791 0.480 0.238 0.087 0.086 0.914
2 sample (a) 0.003 0.055 0.039 0.845 0.155 0.013 0.084 0.065 0.867 0.133 0.018 0.117 0.087 0.859 0.141
2 sample (b) 0.002 0.055 0.040 0.846 0.154 0.013 0.086 0.066 0.871 0.129 0.018 0.122 0.089 0.858 0.142
3 sample (a) 0.005 0.046 0.044 0.931 0.069 0.010 0.083 0.077 0.939 0.061 0.016 0.123 0.112 0.914 0.086
3 sample (b) 0.005 0.048 0.045 0.934 0.066 0.013 0.083 0.078 0.942 0.058 0.018 0.119 0.113 0.919 0.081
Double est. 0.006 0.054 0.043 0.865 0.135 0.020 0.080 0.069 0.886 0.114 0.028 0.109 0.092 0.884 0.116
MV-All -0.005 0.157 0.161 0.957 0.043 0.003 0.192 0.184 0.946 0.054 0.001 0.211 0.206 0.947 0.053
Oracle 0.002 0.029 0.030 0.947 0.053 0.004 0.050 0.049 0.943 0.057 0.006 0.078 0.073 0.928 0.072
Scenario 4: p = 80, k = 90
IVW 0.097 0.109 0.042 0.381 0.619 0.291 0.196 0.068 0.189 0.811 0.466 0.245 0.087 0.110 0.890
2 sample (a) 0.004 0.055 0.041 0.850 0.150 0.013 0.093 0.070 0.847 0.153 0.035 0.124 0.096 0.854 0.146
2 sample (b) 0.005 0.055 0.041 0.857 0.143 0.011 0.096 0.072 0.851 0.149 0.035 0.129 0.100 0.858 0.142
3 sample (a) 0.005 0.047 0.046 0.942 0.058 0.011 0.092 0.085 0.923 0.077 0.019 0.139 0.133 0.945 0.055
3 sample (b) 0.005 0.049 0.047 0.944 0.056 0.011 0.096 0.088 0.933 0.067 0.017 0.144 0.134 0.946 0.054
Double est. 0.008 0.055 0.046 0.884 0.116 0.021 0.088 0.076 0.889 0.111 0.048 0.119 0.108 0.871 0.129
Oracle 0.002 0.029 0.030 0.956 0.044 0.003 0.051 0.049 0.940 0.060 0.005 0.073 0.074 0.950 0.050
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at a genome-wide significance level of 5 × 10−8. Summarized associations between these genetic
variants and urate concentration were produced from a combination of published meta-analyses.
The associations between the genetic variants and coronary heart disease were obtained from the
CARDIoGRAMplusC4D study. In addition, eight potential pleiotropic covariates were identified:
Fasting glucose, BMI, type 2 diabetes, HDL cholesterol, LDL cholesterol, triglycerides, systolic
blood pressure and diastolic blood pressure. These covariates were chosen as risk factors which
have been shown observationally to be associated with increased urate concentration, and are also
known risk factors for coronary heart disease. By examining the associations between the 31 genetic
variants and the covariates, White et al. (2016) concluded that four of them were potential sources
of pleiotropy: HDL cholesterol, triglycerides, systolic blood pressure and diastolic blood pressure.
A Mendelian randomization analysis ignoring covariates suggests that urate concentration has a
causal effect on coronary heart disease. However, when including the covariates in the model,
the results suggest that there is no causal effect. This is supported by Bowden et al. (2017), who
analysed the same data using the MR-Egger method.
We re-analysed the causal effect of urate concentration on coronary heart disease using our
regularization procedure. Details of each of the data sources for the genetic variant associations
are given in the Appendix (noting there are some differences in the data sources used here to those
used by White et al., 2016). Figure 3 shows the values of the coefficients for the genetic variant-
risk factor and genetic-variant-covariate associations produced by the regularization procedure for
increasing values of λ. The value of λ used in the final model was chosen by performing 10-fold
cross-validation 100 times and taking the mean minimizer of the mean squared error. This value
is indicated in Figure 3 by the vertical dashed line. The procedure identified two covariates that
should be included in the analysis: diastolic blood pressure and BMI. This suggests that pleiotropy
is being caused by these two covariates only. Interestingly, BMI was not identified by White et al.
(2016) as a covariate to be included in the model. Furthermore, HDL cholesterol was the final
covariate to be included using the regularization method, whereas it was one of the four chosen by
White et al. (2016).
We performed multivariable Mendelian randomization analyses using five sets of covariates:
no covariates; all covariates; the four covariates identified by White et al. (2016); diastolic blood
pressure only; and diastolic blood pressure and BMI. Table 5 shows the estimates of the log causal
odds ratio for each model, as well as their standard errors and 95% confidence intervals (computed
using a random effects model and the normal distribution). In agreement with the previous studies,
the results suggest that urate concentration has a causal effect on coronary heart disease when
ignoring covariates. When covariates are included, the results suggest that there is no causal effect.
The causal effect estimate when only diastolic blood pressure (0.036) or diastolic blood pressure and
BMI (0.034) were included are close to the estimates obtained by including all covariates (0.036)
or the set of covariates chosen by White et al. (2016) (0.038).
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Table 5: Estimates, standard errors (SE) and 95% confidence intervals of the log causal odds ratio
for coronary heart disease per one standard deviation increase in plasma urate concentration levels.
Covariates included Estimate SE 95% Confidence interval
None 0.104 0.040 (0.025, 0.182)
All 0.036 0.031 (-0.025, 0.096)
HDL, Tri, SBP & DBP 0.038 0.029 (-0.020, 0.095)
DBP 0.036 0.027 (-0.017, 0.089)
DBP & BMI 0.034 0.027 (-0.019, 0.087)
We use a covariate balancing plot which shows the correlation between the genetic variant-
risk factor / covariate associations and the residuals obtained after regressing the genetic variant-
outcome associations on the genetic variant-covariate associations for each set of covariates con-
sidered. If there is no pleiotropy exerted by the covariates, or there is pleiotropy but the model
has accounted for it, the correlations with the genetic variant-covariate associations will be close to
zero. The plot thus demonstrates two things: the strength of the association between the instru-
ments and the risk factor when controlling for the different sets of covariates (shown by the size
of the correlation with urate concentration), and how well each model has balanced the pleiotropic
effects (shown by the size of the correlations with the covariates). Figure 4 shows that, when all
covariates are ignored, the genetic variant-risk factor correlation is the strongest, but there are also
strong correlations with all other covariates except for glucose fasting. When all covariates are
included, the genetic variant-risk factor strength is somewhat weaker, but all covariates are close
to uncorrelated with the residuals. When the four covariates of White et al. (2016) are included,
the covariates are reasonably balanced except for BMI, and a similar pattern is seen when diastolic
blood pressure only is included. When diastolic blood pressure and BMI are included, a similar
pattern of instrument-exposure correlation and covariate balance is seen as in the case of the full
multivariable model.
It should be noted that the analysis here has been performed in a two-sample framework,
implying that the confidence interval from the model chosen by the regularization procedure could
be too narrow. This would be the case if further covariates should be included to account for
pleiotropy. However, the covariate balancing plot suggests that the inclusion of more covariates
is not needed. Furthermore, since we have a finding of no causal effect, widening the confidence
interval will only strengthen the evidence behind this finding.
7 Discussion
In this paper, we have presented a method for estimating a causal effect of a risk factor on an
outcome in a Mendelian randomization setting in the face of pleiotropy. The method does not
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Figure 3: Estimates of regression coefficients for the genetic variant-risk factor association and
the eight genetic variant-covariate associations for different values of λ. The dashed vertical line
indicates the value of λ chosen by cross-validation.
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Figure 4: Correlation between the genetic variant-risk factor association and genetic variant-
covariate associations, and the residuals obtained after regressing the genetic variant-outcome as-
sociation on each set of genetic variant-covariate associations.
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require any of the genetic variants to be valid instruments and can be performed using summarized
data only. By controlling for covariates that have pathways to the outcome which bypass the
risk factor we remove the bias that arises due to these covariates. By not controlling for further
covariates unnecessarily, we gain a more precise estimate than we would from a full multivariable
model. Furthermore, we can consider cases where there are more covariates than instruments,
which cannot be handled by standard multivariable Mendelian randomization techniques. We
also discussed different ways of constructing confidence intervals for the causal effect. Simulations
suggest that our proposed three sample approach produces valid confidence intervals and can be
used to infer the presence of a causal effect.
The regularization method can be used as a model selection tool which identifies mechanisms
by which sets of genetic variants influence an outcome. In the study looking at the effect of urate
concentration on coronary heart disease, the method suggested that pleiotropy was being caused by
diastolic blood pressure and BMI. This is in contrast to the previous finding suggesting that HDL
cholesterol, triglycerides and systolic blood pressure, but not BMI, should be accounted for.
Although the method was derived for the case where there are no causal pathways between the
risk factor and covariates, the method will still work when such pathways exist. In practice, there
may be many pathways among the covariates if the set of potential covariates is chosen by taking
all plausible traits from a GWAS database, many of which may be highly correlated. Two possible
scenarios relating to causal pathways between the risk factor and the covariates are illustrated via
the directed acyclic graphs in Figure 5. The first is where covariates are predictors of both the risk
factor and the outcome. The second is where covariates are mediators of the causal effect of the
risk factor on the outcome (also known as vertical pleiotropy). In the latter case, care needs to be
taken over the interpretation of the causal effect estimate. The estimate in this case will be of the
direct causal effect of the risk factor on the outcome, and will not include the indirect effect via
the mediator(s) (Burgess et al., 2017; Sanderson et al., 2018). Hence an alternative interpretation
of the results of the applied example is that the covariates (in particular, diastolic blood pressure)
are mediators of the effect of urate concentration on coronary heart disease.
We note that we are assuming linearity in the relationships between the genetic variants and
the risk factor, covariates and the outcome. Although we have derived the method as though we
have a continuous outcome, an advantage of using summarized data is that it allows us to also
consider binary outcomes. In this case, the βˆY j ’s represent estimates of log odds ratios obtained
by fitting logistic regression models. Note, however, that, due to the non-collapsibility of the odds
ratio, causal effect estimates will tend toward the null (Vansteelandt et al., 2011; Bowden et al.,
2017).
In summary, the method we have developed provides a causal effect estimator in a Mendelian
randomization setting where potentially all genetic instruments are invalid due to pleiotropy via
a possibly high-dimensional set of covariates. The estimator is robust to measured pleiotropy and
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Figure 5: Directed acyclic graphs showing the cases where W has a causal effect on both X and
Y (left graph) and when W is a mediator of the causal effect of X on Y (right graph). Here, W
represents one or more, possibly correlated, covariates.
more efficient than existing methods.
8 Software
R code for performing the proposed method and for generating the simulation results are available
at https://github.com/aj-grant/mvcovreg.
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A Appendix
A.1 Equivalence of covariate balancing allele scores and the multivari-
able inverse-variance weighted method
Let B =
[
βˆX βˆW
]
. The multivariable inverse-weighted estimator for
[
θ δ′
]
′
is obtained by
regressing S1/2βˆY on S
1/2B, that is,
(B′SB)
−1
(
B′SβˆY
)
=
[
βˆ′XSβˆX βˆ
′
XSβˆW
βˆ′WSβˆX βˆ
′
WSβˆW
]
−1 [
βˆ′XSβˆY
βˆ′WSβˆY
]
.
The estimator of θ is the first entry of this vector. By the matrix inversion lemma, the top row of
the first term on the right hand side is
[
1
V −
1
V
(
βˆ′XSβˆW
)(
βˆ′WSβˆW
)
−1
]
where
V = βˆ′XSβˆX −
(
βˆ′XSβˆW
)(
βˆ′WSβˆW
)
−1 (
βˆ′WSβˆX
)
.
The estimator for θ is thus
βˆ′XSβˆY −
(
βˆ′XSβˆW
)(
βˆ′WSβˆW
)
−1 (
βˆ′WSβˆY
)
βˆ′XSβˆX −
(
βˆ′XSβˆW
)(
βˆ′WSβˆW
)
−1 (
βˆ′WSβˆX
)
=
{
βˆX − βˆW
(
βˆ′WSβˆW
)
−1 (
βˆ′WSβˆX
)}′
SβˆY{
βˆX − βˆW
(
βˆ′WSβˆW
)
−1 (
βˆ′WSβˆX
)}′
SβˆX
=
α˜′SβˆY
α˜′SβˆX
.
A.2 Derivation of the two step estimation procedure
We wish to find
argmin
θ,δ
1
2
(
βˆY − θβˆX − βˆW δ
)
′
S
(
βˆY − θβˆX − βˆW δ
)
+ λ
k∑
i=1
|δi| . (11)
Following the notation of Kang et al. (2016), we let PM =M (M
′M)
−1
M ′ for some matrixM with
d rows such that M ′M is invertible, and PM⊥ = Id − PM . Note that PMPM = PM⊥PM⊥ = PM ,
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PMPM⊥ = 0, PM +PM⊥ = Id and PMM =M . Denoting by ‖·‖2 the ℓ2 norm, (11) can be written
as
1
2
argmin
θ,δ
∥∥∥S1/2 (βˆY − θβˆX − βˆW δ)∥∥∥2
2
+ λ
k∑
i=1
|δi| . (12)
Let b = S1/2βˆX . Then
1
2
∥∥∥S1/2 (βˆY − θβˆX − βˆW δ)∥∥∥2
2
+ λ
k∑
i=1
|δi|
=
1
2
∥∥∥(Pb + Pb⊥)S1/2 (βˆY − θβˆX − βˆW δ)∥∥∥2
2
+ λ
k∑
i=1
|δi|
=
1
2
∥∥∥PbS1/2 (βˆY − θβˆX − βˆW δ)∥∥∥2
2
+
1
2
∥∥∥Pb⊥S1/2 (βˆY − θβˆX − βˆW δ)∥∥∥2
2
+ λ
k∑
i=1
|δi|
=
1
2
∥∥∥PbS1/2 (βˆY − βˆW δ)− θS1/2βˆX∥∥∥2
2
+
1
2
∥∥∥Pb⊥S1/2βˆY − Pb⊥S1/2βˆW δ∥∥∥2
2
+ λ
k∑
i=1
|δi| . (13)
The second and third terms of (13) are independent of θ. The first term of (13) can be set to zero
for any value of δ = δ∗ by putting
θ =
(
βˆY − βˆW δ
∗
)
′
SβˆX
βˆ′XSβˆX
. (14)
Thus, (12) can be solved by minimising the second and third terms of (13) with respect to δ, then
setting θ according to (14). This is the two step procedure.
A.3 Data sources for the applied analysis
The associations between the genetic variants and urate concentration were taken from White et al.
(2016). Note that, although the singificance level for inclusion of a genetic variant was 5 × 10−8,
one variant (rs164009) which had a p-value larger than 5× 10−8, and less than 5× 10−7, was also
included on the basis of a known biological role in urate metabolism. The associations between the
genetic variants and coronary heart disease as well as the covariates were taken from GWAS data as
summarized in Table 6, and accessed using PhenoScanner (Staley et al., 2016; Kamat et al., 2019).
Note that the analysis by White et al. (2016) used the 2013 CARDIoGRAMplusC4D dataset,
whereas here we use the 2015 dataset. Similarly, White et al. (2016) used the 2012 dataset from
DIAGRAM and the 2010 dataset from GIANT, whereas here we use the 2017 and 2015 datasets,
respectively. Finally, White et al. (2016) obtained genetic variant associations with the blood pres-
sure traits from the ICBP consortium, whereas here we use the 2017 results from the analysis of UK
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Table 6: Sources of associations between the 31 genetic variants and the covariates.
Trait Consortium Study Sample Size
Coronary heart disease CARDIoGRAMplusC4D Nikpay et al. (2015) 184 305
Fasting glucose MAGIC Dupuis et al. (2010) 46 186
BMI GIANT Locke et al. (2015) 339,224
Type 2 diabetes DIAGRAM Scott et al. (2017) 159 208
HDL cholesterol GLGC Willer et al. (2013) 187 167
LDL cholesterol GLGC Willer et al. (2013) 173 082
Triglycerides GLGC Willer et al. (2013) 177 861
Systolic blood pressure Neale Lab 2017 results 337 199
Diastolic blood pressure Neale Lab 2017 results 337 199
Biobank by the Neale Lab (http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank).
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